Senti Biosciences Bilan de santé

Santé financière contrôle des critères 3/6

Senti Biosciences possède un total de capitaux propres de $16.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $57.7M et de $41.7M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$10.48m
Fonds propres	US$15.99m
Total du passif	US$41.73m
Total des actifs	US$57.72m

Mises à jour récentes de la santé financière

Recent updates

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Dec 28

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Sep 27

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Sep 22

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Aug 16

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Jun 13

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SNTI ( $17.4M ) dépassent ses passifs à court terme ( $9.1M ).

Passif à long terme: Les actifs à court terme de SNTI ( $17.4M ) ne couvrent pas ses passifs à long terme ( $32.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SNTI est sans dette.

Réduire la dette: SNTI n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SNTI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: SNTI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 14.3 % chaque année

Senti Biosciences Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Nasdaq Grants Senti Biosciences’ Request to Transfer the Listing of its Common Stock from The Nasdaq Global Market Tier to The Nasdaq Capital Market Tier, Effective January 25, 2024

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Recent updates

Senti Biosciences, Inc. Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Biosciences, Inc., Annual General Meeting, Jul 10, 2024

Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024

Nasdaq Grants Senti Biosciences’ Request to Transfer the Listing of its Common Stock from The Nasdaq Global Market Tier to The Nasdaq Capital Market Tier, Effective January 25, 2024

Spark Therapeutics, Inc. Announces Workforce Reduction

Spark Therapeutics, Inc. Announces Workforce Reduction

Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer

New minor risk - Share price stability

Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting

Consensus EPS estimates upgraded to US$1.54 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.92 loss

Senti Biosciences, Inc. Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Senti Biosciences, Inc. Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Second quarter 2022 earnings released

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Senti Biosciences, Inc. Announces Resignation of Curt A. Herberts III, Chief Operating Officer Effective as of August 19, 2022

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Senti Biosciences, Inc. Announces Board Appointments

Less than half of directors are independent

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines